BRAF and melanoma: Moser et al (2019) retrospectively assessed electronic health record (EHR) data of patients with BRAF‐mutant melanoma who received first‐line (1L) treatment with aPD‐1, BRAF/MEKi, or nivolumab/ipilimumab.18